Picture of Senzime AB (publ) logo

SEZI — Senzime AB (publ) News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Sweden's Senzime Q2 sales fall on hospital contract delay

Sweden's Senzime Q2 sales fall on hospital contract delay


Overview

  • Sweden medical device firm's Q2 net sales fell 4% yr/yr, US sales down 6%

  • Q2 gross margin improved to 65.7% from 61.8% last yr

  • Company signed strategic partnership with Philips Medical Systems to expand global reach


Outlook

  • Senzime aims to achieve profitability by Q4 2026

  • Company expects continued margin improvements and disciplined cost management

  • Senzime expects additional U.S. tariff repayments totaling USD 350 thousand over coming quarters


Result Drivers

  • SENSOR SALES GROWTH - Co said recurring sensor sales increased 48% in local currencies, now making up about 80% of revenue, driven by greater utilization of TetraGraph systems

  • US MARKET WEAKNESS - Co said Q2 sales were affected by a slower US market and delays in expected hospital contracts

  • MARGIN IMPROVEMENT - Co attributed improved gross margin to increased operational focus and cost reductions, despite ongoing impact from US tariffs


Company press release: ID:nMFN6WPDXs


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Miss

SEK 24.67 mln

SEK 31 mln (1 Analyst)

Q2 EPS

-SEK 0.14

Q2 Adjusted Gross Margin

65.70%


Analyst Coverage

  • Wall Street's median 12-month price target for Senzime AB (publ) is SEK9.50, about 130.9% above its July 15 closing price of SEK4.12


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Senzime AB (publ)

See all news